According to the research of R & D companies conducted by Turkishtime magazine, our company took its place in the top ranks in 2019, as in 2018
250 Largest Companies By R & D Spending 2019
2019 Top 100 according to number of projects carried out in R & D Center
As Argis ilaç, we continue to produce projects by conducting research and development for our country.
Together with our Board of directors and all our employees, We celebrated the license of our D3 TOTAL 150,000 IU/10ML ORAL Drops, solution product
Side Effect/Adverse Reaction Notification:
For notifications of side effects/adverse reactions related to our products, you can consult your doctor or pharmacist, contact the authorized health authority, or fill out the form below (Tufam adverse reaction Notification Form email@example.com you can send it to his address.
In addition, you can contact us on 0216 385 93 33 for reports of side effects/adverse reactions.
Click here to download the Tufam adverse reaction Notification Form.
Notifications about side effects/adverse reactions are collected in accordance with legal obligations to benefit public health protection.
During the follow-up of notifications about side effects/adverse reactions, you can be returned to you using your contact information to obtain more information.
At least one of your phone or email address information must be notified so that we can get back to you.
In September 2018 as Argis Pharmaceuticals, t.C. We were declared as A R & D Center by the Ministry of industry and Technology. 7 on 19.11.2019. at the technology development zones and R & D center Award Ceremony held in si, we received our R & D Center certificate. At the 7th Summit, attended by Minister of industry and Technology Mustafa Varank, as well as senior managers of Ministry institutions and organizations, 39 companies in 13 different categories received awards and 735 companies received R & D and Design Center certificates.